Journal article
Polyphenol-Functionalized Cubosomes as Thrombolytic Drug Carriers
H Yu, JS Palazzolo, Y Ju, B Niego, S Pan, CE Hagemeyer, F Caruso
Advanced Healthcare Materials | WILEY | Published : 2022
Abstract
The safe administration of thrombolytic agents is a challenge for the treatment of acute thrombosis. Lipid-based nanoparticle drug delivery technologies present opportunities to overcome the existing clinical limitations and deliver thrombolytic therapy with enhanced therapeutic outcomes and safety. Herein, lipid cubosomes are examined as nanocarriers for the encapsulation of thrombolytic drugs. The lipid cubosomes are loaded with the thrombolytic drug urokinase-type plasminogen activator (uPA) and coated with a low-fouling peptide that is incorporated within a metal–phenolic network (MPN). The peptide-containing MPN (pep-MPN) coating inhibits the direct contact of uPA with the surrounding e..
View full abstractRelated Projects (2)
Grants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
H.Y. and J.S.P. contributed equally to this work. The authors thank Dr. Chan-Jin Kim for operating EDX elemental mapping characterization. This research was funded and supported by a National Health and Medical Research Council (NHMRC) Project Grant (GNT1138361, C.E.H. and F.C.). F.C. and C.E.H. acknowledge the award of an NHMRC Senior Principal Research Fellowship (GNT1135806) and an NHMRC Research Fellowship (GNT1154270), respectively. J.S.P. acknowledges support from Australian Rotary Health, Rotary District 9830, and the Australian Government Research Training Program (RTP) Scholarship. Part of this research was undertaken on the SAXS/WAXS beamline at the Australian Synchrotron, part of the Australian Nuclear Science and Technology Organisation (ANSTO).